{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T07:43:47Z","timestamp":1773647027373,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Silesia in Katowice","award":["PCN-CBN-640-2-1-438\/22"],"award-info":[{"award-number":["PCN-CBN-640-2-1-438\/22"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. This justifies attempts to identify second-line drugs for the treatment of dysthymia. In an open and naturalistic case study, five patients diagnosed with dysthymia in whom at least one antidepressant treatment was ineffective were treated with amantadine. In the age- and gender-matched external control group, patients were treated with sertraline at 100 mg\/day. Depressive symptoms were assessed using HDRS-17. Two men and three women were treated with 100 mg amantadine for 3 months with 3\u20135 months follow-up. After 1 month of treatment with amantadine, a significant reduction in the intensity of depressive symptoms was achieved in all patients, and the clinical improvement increased over the next 2 months of treatment. No deterioration in well-being was observed in any patient after discontinuation of amantadine. The effect of amantadine treatment was comparable to that of sertraline treatment in patients with dysthymia who improved with this drug. The present study indicates that amantadine is an effective and well-tolerated drug in the treatment of dysthymia. Amantadine may be associated with a quick improvement in symptoms in the treatment of dysthymia. Treatment with this drug seems to be associated with good tolerability and persistency of the therapeutic effect after the discontinuation of the treatment.<\/jats:p>","DOI":"10.3390\/ph16060897","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T02:26:56Z","timestamp":1687228016000},"page":"897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Amantadine in Treatment of Dysthymia\u2014The Pilot Case Series Study"],"prefix":"10.3390","volume":"16","author":[{"given":"Marek","family":"Krzystanek","sequence":"first","affiliation":[{"name":"Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Martyniak","sequence":"additional","affiliation":[{"name":"Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Pa\u0142asz","sequence":"additional","affiliation":[{"name":"Department of Histology, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-752 Katowice, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-7547","authenticated-orcid":false,"given":"Katarzyna","family":"Ska\u0142acka","sequence":"additional","affiliation":[{"name":"Institute of Psychology, University of Opole, 45-040 Opole, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Chwalba","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 41-808 Zabrze Rokitnica, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Wierzbi\u0144ski","sequence":"additional","affiliation":[{"name":"Psychiatry Outpatient Clinic, 91-498 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S2215-0366(20)30099-7","article-title":"Review of dysthymia and persistent depressive disorder: History, correlates, and clinical implications","volume":"7","author":"Schramm","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1176\/ajp.2006.163.5.872","article-title":"Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression","volume":"163","author":"Klein","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/14656566.2019.1637419","article-title":"Current pharmacotherapeutic approaches for dysthymic disorder and persistent depressive disorder","volume":"20","author":"Carta","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Meister, R., von Wolff, A., Mohr, H., H\u00e4rter, M., Nestoriuc, Y., H\u00f6lzel, L., and Kriston, L. (2016). Comparative Safety of Pharmacologic Treatments for Persistent Depressive Disorder: A Systematic Review and Network Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0153380"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(71)90153-X","article-title":"Amantadine in depression","volume":"2","author":"Vale","year":"1971","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2007-979191","article-title":"Possible use of amantadine in depression","volume":"32","author":"Huber","year":"1999","journal-title":"Pharmacopsychiatry"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/acps.12712","article-title":"Dopaminergic agents in the treatment of bipolar depression: A systematic review and meta-analysis","volume":"135","author":"Szmulewicz","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0447.2007.01058.x","article-title":"Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder","volume":"434","author":"Berk","year":"2007","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"ref_10","first-page":"778","article-title":"Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression","volume":"59","author":"Skuza","year":"2007","journal-title":"Pharmacol. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00004850-200303000-00005","article-title":"Amantadine as augmentation therapy in the management of treatment-resistant depression","volume":"18","author":"Stryjer","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Krzystanek, M., and Pa\u0142asz, A. (2020). Possibility of a New Indication for Amantadine in the Treatment of Bipolar Depression-Case Series Study. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100326"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0706743716664885","article-title":"Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults","volume":"62","author":"MacQueen","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.pbb.2018.12.010","article-title":"Amantadine enhances nigrostriatal and mesolimbic dopamine function in the rat brain in relation to motor and exploratory activity","volume":"179","author":"Nikolaus","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0361-9230(96)00211-0","article-title":"Inhibitory effect of MK-801 on amantadine-induced dopamine release in the rat striatum","volume":"41","author":"Takahashi","year":"1996","journal-title":"Brain Res. Bull."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1037\/0021-843X.103.4.625","article-title":"A dual-task analysis of resource allocation in dysthymia and anhedonia","volume":"103","author":"Yee","year":"1994","journal-title":"J. Abnorm. Psychol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00228-021-03216-8","article-title":"Use of ketamine and esketamine for depression: An overview of systematic reviews with meta-analyses","volume":"78","author":"Lima","year":"2022","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1001\/jama.2016.3445","article-title":"Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006\u20132015","volume":"315","author":"Wong","year":"2016","journal-title":"JAMA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"172732","DOI":"10.1016\/j.ejphar.2019.172732","article-title":"Off-label uses of drugs for depression","volume":"865","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_20","first-page":"28","article-title":"Leczenie poza wskazaniami z ChPL [Off-label treatment in the SmPC]","volume":"7\u20138","author":"Kosiorek","year":"2022","journal-title":"Gaz. Lek."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s40264-020-00944-1","article-title":"A framework for methodological choice and evidence assessment for studies using external comparators from real-world data","volume":"43","author":"Gray","year":"2020","journal-title":"Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/6\/897\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:56:22Z","timestamp":1760126182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/6\/897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ph16060897"],"URL":"https:\/\/doi.org\/10.3390\/ph16060897","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}